Fri, Jul 11, 2014, 12:22 PM EDT - U.S. Markets close in 3 hrs 38 mins

Recent

% | $
Quotes you view appear here for quick access.

Neurocrine Biosciences Inc. Message Board

  • pharmaherokz pharmaherokz Aug 15, 2011 8:17 AM Flag

    IGXT (Mcap 27 M) // PDUFA date 13 Nov 2011

    Dip creates a lifetime buying opportunity ..Do your own research and best luck .

    FDA accepted the resubmission >> NEW PDUFA date 13 November 2011 .Big Partnerdeal for lead drug CPI-300 in 3Q 2011.

    IGXT has 3.7 M in Cash enuff till 2013 excluding revenue from CPI-300 and upfront payment from new Partnerdeal which is imminent .

    PRICE TARGET 3++ DOLLAR

    Intelgenx (IGXT.OB)

    Market Cap : 27 M$
    Cash: 3.7 M$
    Price : 0,66 $

    Shares Out : 45 M ( 20 M shares are held by Insiders + Institutions)


    IntelGenx Announces New PDUFA Date for Its Single Dose 450 mg Bupropion Hydrochloride Tablet

    Press Release Source: IntelGenx Corp. On Tuesday June 14, 2011, 6:00 am EDT

    IntelGenx Corp announced that the U.S. Food and Drug Administration ("FDA") has accepted the Company's resubmission of its antidepressant CPI-300 New Drug Application 505(b)(2) in response to the February 2010 Complete Response Letter ("CRL") as a complete, Class 2 response. In addition, the FDA has established November 13, 2011 as its target action date under the Prescription Drug User Fee Act ("PDUFA"). CPI-300 is a novel, high strength of Bupropion Hydrochloride (HCl), the active ingredient in Wellbutrin XL®.

    .......................................

 
NBIX
14.03-0.13(-0.92%)12:19 PMEDT

Trending Tickers

i
Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.